ViiV Healthcare announced that dolutegravir-lamivudine (DTG/3TC; Dovato) is now available in a blister pack in the United States.
The combined DTG/3TC is approved as a complete regimen to treat HIV-1 infection in adults who are treatment-naive or to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of the therapy.
“The Dovato blister pack is designed to help address some of the challenges we hear from the HIV community, which include stigma and convenience, and offers a discreet package which may fit more seamlessly into people’s daily routines,” said Lynn Baxter, the head of North America at ViiV Healthcare.
The blister pack is a monthly 30-count box containing five sheets of tablets. Created based on insights from the HIV community, each sheet is about the size of a credit card and perforated, and designed to be small, discreet and not bulky. The sheets allow people living with HIV to view the number of pills left and track their doses.
The FDA approved the DTG/3TC blister pack on Nov. 3, 2023. ViiV Healthcare also will continue to offer DTG/3TC in the 30-count pill bottle.
DTG/3TC is a once-daily, single-pill, two-drug regimen that combines the integrase strand transfer inhibitor DTG with the nucleoside reverse transcriptase inhibitor 3TC.
From company press materials.
